In patients with indeterminate colitis, does anti-TNF therapy result in similar clinical remission rates compared with standard medical therapy (e.g., immunomodulators, steroids)

What is known

- The only IC-specific anti-TNF data come from a single retrospective series of 20 patients with severe, medically refractory IC in whom infliximab produced a complete response in 14 (70%). ¹

What is unknown / caveats

- There are no randomized or comparative trials of anti-TNF versus standard medical therapy (immunomodulators, steroids) specifically in indeterminate colitis, and no prospective medical treatment trials in IC have been reported at all. ^2,3 - That single series is an uncontrolled cohort, so it cannot establish whether remission rates are similar to, better than, or worse than standard therapy.

## References

1. Papadakis KA, Treyzon L, Abreu MT, Fleshner PR, Targan SR, Vasiliauskas EA. Infliximab in the treatment of medically refractory indeterminate colitis. Aliment Pharmacol Ther. 2003;18(7):741-7. PMID: 14510748.

2. Tremaine WJ. Review article: Indeterminate colitis--definition, diagnosis and management. Aliment Pharmacol Ther. 2007;25(1):13-7. PMID: 17229217.

3. Burakoff R. Indeterminate colitis: clinical spectrum of disease. J Clin Gastroenterol. 2004;38(5 Suppl 1):S41-3. PMID: 15115931.

For educational use only, not a substitute for clinical judgement or medical advice. Consult qualified clinicians for diagnosis and treatment decisions. This tool may contain errors; use the flag button below to report inaccurate or harmful content.

---

_Draft, generated by the IBDology RAG and not yet clinician-reviewed. Answers are grounded in the retrieved literature listed above; a high faithfulness score means the answer matches its sources, not that the sources are correct._